Mitochondrial dysfunction and neurodegeneration in multiple sclerosis

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Multiple sclerosis (MS) has traditionally been considered an autoimmune inflammatory disorder leading to demyelination and clinical debilitation as evidenced by our current standard anti-inflammatory and immunosuppressive treatment regimens. While these approaches do control the frequency of clinical relapses, they do not prevent the progressive functional decline that plagues many people with MS. Many avenues of research indicate that a neurodegenerative process may also play a significant role in MS from the early stages of disease, and one of the current hypotheses identifies mitochondrial dysfunction as a key contributing mechanism. We have hypothesized that pathological permeability transition pore (PTP) opening mediated by reactive oxygen species (ROS) and calcium dysregulation is central to mitochondrial dysfunction and neurodegeneration in MS. This focused review highlights recent evidence supporting this hypothesis, with particular emphasis on our in vitro and in vivo work with the mitochondria-targeted redox enzyme p66ShcA.

Original languageEnglish (US)
Article numberArticle 169
JournalFrontiers in Physiology
Volume4 JUL
DOIs
StatePublished - 2013

Fingerprint

Multiple Sclerosis
Plague
Demyelinating Diseases
Immunosuppressive Agents
Oxidation-Reduction
Permeability
Reactive Oxygen Species
Mitochondria
Anti-Inflammatory Agents
Calcium
Recurrence
Enzymes
Research

Keywords

  • Mitochondria
  • Multiple sclerosis
  • Neurodegeneration
  • Neuronal viability
  • P66Shca

ASJC Scopus subject areas

  • Physiology
  • Physiology (medical)

Cite this

Mitochondrial dysfunction and neurodegeneration in multiple sclerosis. / Su, Kimmy; Bourdette, Dennis; Forte, Michael.

In: Frontiers in Physiology, Vol. 4 JUL, Article 169, 2013.

Research output: Contribution to journalArticle

@article{6a637488ef124d12a4043b5e227bce64,
title = "Mitochondrial dysfunction and neurodegeneration in multiple sclerosis",
abstract = "Multiple sclerosis (MS) has traditionally been considered an autoimmune inflammatory disorder leading to demyelination and clinical debilitation as evidenced by our current standard anti-inflammatory and immunosuppressive treatment regimens. While these approaches do control the frequency of clinical relapses, they do not prevent the progressive functional decline that plagues many people with MS. Many avenues of research indicate that a neurodegenerative process may also play a significant role in MS from the early stages of disease, and one of the current hypotheses identifies mitochondrial dysfunction as a key contributing mechanism. We have hypothesized that pathological permeability transition pore (PTP) opening mediated by reactive oxygen species (ROS) and calcium dysregulation is central to mitochondrial dysfunction and neurodegeneration in MS. This focused review highlights recent evidence supporting this hypothesis, with particular emphasis on our in vitro and in vivo work with the mitochondria-targeted redox enzyme p66ShcA.",
keywords = "Mitochondria, Multiple sclerosis, Neurodegeneration, Neuronal viability, P66Shca",
author = "Kimmy Su and Dennis Bourdette and Michael Forte",
year = "2013",
doi = "10.3389/fphys.2013.00169",
language = "English (US)",
volume = "4 JUL",
journal = "Frontiers in Physiology",
issn = "1664-042X",
publisher = "Frontiers Research Foundation",

}

TY - JOUR

T1 - Mitochondrial dysfunction and neurodegeneration in multiple sclerosis

AU - Su, Kimmy

AU - Bourdette, Dennis

AU - Forte, Michael

PY - 2013

Y1 - 2013

N2 - Multiple sclerosis (MS) has traditionally been considered an autoimmune inflammatory disorder leading to demyelination and clinical debilitation as evidenced by our current standard anti-inflammatory and immunosuppressive treatment regimens. While these approaches do control the frequency of clinical relapses, they do not prevent the progressive functional decline that plagues many people with MS. Many avenues of research indicate that a neurodegenerative process may also play a significant role in MS from the early stages of disease, and one of the current hypotheses identifies mitochondrial dysfunction as a key contributing mechanism. We have hypothesized that pathological permeability transition pore (PTP) opening mediated by reactive oxygen species (ROS) and calcium dysregulation is central to mitochondrial dysfunction and neurodegeneration in MS. This focused review highlights recent evidence supporting this hypothesis, with particular emphasis on our in vitro and in vivo work with the mitochondria-targeted redox enzyme p66ShcA.

AB - Multiple sclerosis (MS) has traditionally been considered an autoimmune inflammatory disorder leading to demyelination and clinical debilitation as evidenced by our current standard anti-inflammatory and immunosuppressive treatment regimens. While these approaches do control the frequency of clinical relapses, they do not prevent the progressive functional decline that plagues many people with MS. Many avenues of research indicate that a neurodegenerative process may also play a significant role in MS from the early stages of disease, and one of the current hypotheses identifies mitochondrial dysfunction as a key contributing mechanism. We have hypothesized that pathological permeability transition pore (PTP) opening mediated by reactive oxygen species (ROS) and calcium dysregulation is central to mitochondrial dysfunction and neurodegeneration in MS. This focused review highlights recent evidence supporting this hypothesis, with particular emphasis on our in vitro and in vivo work with the mitochondria-targeted redox enzyme p66ShcA.

KW - Mitochondria

KW - Multiple sclerosis

KW - Neurodegeneration

KW - Neuronal viability

KW - P66Shca

UR - http://www.scopus.com/inward/record.url?scp=84884544192&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884544192&partnerID=8YFLogxK

U2 - 10.3389/fphys.2013.00169

DO - 10.3389/fphys.2013.00169

M3 - Article

C2 - 23898299

AN - SCOPUS:84884544192

VL - 4 JUL

JO - Frontiers in Physiology

JF - Frontiers in Physiology

SN - 1664-042X

M1 - Article 169

ER -